Gut Liver.  2014 Sep;8(5):557-562. 10.5009/gnl13264.

Validation of Group B Borderline Resectable Pancreatic Cancer: Retrospective Analysis

• Oh TG
• Chung MJ
• Bang S
• Park SW
• Chung JB
• Song SY
• Seong J
• Kang CM
• Lee WJ
• Park JY

• KMID: 2070067
• DOI: http://doi.org/10.5009/gnl13264

Abstract

BACKGROUND/AIMS
Among borderline resectable pancreatic cancer (BRPC), group B BRPC patients have findings that are suggestive but not diagnostic of metastasis. In this study, we attempted to validate whether group B could truly be categorized as a borderline resectable group.
METHODS
We placed the BRPC patients into group A or group B. The survival outcomes were compared between the groups.
RESULTS
A total of 53 patients with pancreatic adenocarcinoma was classified as either group A or B borderline resectable. In group A, 23 (60.5%) of 38 patients underwent pancreatectomy after concurrent chemoradiotherapy or chemotherapy, but in group B, only five (33.3%) of 15 patients underwent pancreatectomy, mainly because of the progression of suspected distant metastasis. There was a significant difference in overall survival (OS) between group A and B patients (median OS, 21.2 months vs 10.2 months, respectively; p=0.007). Of the patients who underwent pancreatectomy, group B had a higher recurrence rate compared to group A (recurrence rate: 11 of 23 patients [47.8%] vs five of five patients [100%], respectively; p=0.033).
CONCLUSIONS
This report is the first to validate the definition of BPRC. Group B had much worse outcomes, and whether group B BRPC can be categorized as BRPC together with group A is questionable.

Keyword

Pancreatic neoplasms; Chemoradiotherapy; Chemotherapy; Prognosis

MeSH Terms

Adenocarcinoma/classification/mortality/pathology/surgery
Adult
Aged
Aged, 80 and over
Chemoradiotherapy
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local
Pancreatectomy
Pancreatic Neoplasms/*classification/mortality/pathology/*surgery
Retrospective Studies
Treatment Outcome